Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | ACP3 | P15309 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12628146 | 1.00 | KIF11 (0.46) | KIF11NR1I2ACP3PTGS2PTPN5 | |
| SCHEMBL3077737 | 0.86 | AOC3 (0.47) | NR1I2 | |
| SCHEMBL1669527 | 0.86 | AOC3 (0.47) | NR1I2 | |
| SCHEMBL44838 | 0.86 | AOC3 (0.47) | NR1I2 | |
| SCHEMBL14593355 | 0.83 | ESR1 (0.48) | NR1I2ALDH1A1 | |
| SCHEMBL8988146 | 0.83 | ESR1 (0.58) | KIF11MMP3BCL2L1CYP3A4 | |
| SCHEMBL309069 | 0.81 | ESR2 (0.55) | PTPN5CYP3A4APP | |
| SCHEMBL1932037 | 0.81 | ESR2 (0.55) | PTPN5CYP3A4APP | |
| SCHEMBL4515042 | 0.81 | PTPN5 (0.51) | KIF11PTPN5CYP2D6 | |
| SCHEMBL12534388 | 0.80 | PTPN5 (0.45) | PTPN5APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291988-A1 | Reversible Inhibitors of Monoamine Oxidase A and B | MERCK FROSST CANADA LTD. (CA) | 2009-11-26 | — | — | US | claimed |
| EP-1893562-A1 | REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B | Merck Frosst Canada Ltd. (CA) | 2008-03-05 | — | — | EP | claimed |
| WO-2006133559-A1 | REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B | MERCK FROSST CANADA LTD. (CA) | 2006-12-21 | — | — | WO | claimed |
| US-7087789-B2 | Methods for nucleophilic fluoromethylation | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2006-08-08 | — | — | US | claimed |
| US-20040230079-A1 | Methods for nucleophilic fluoromethylation | SOUTHERN CALIFORNIA, UNIVERSITY OF | 2004-11-18 | — | — | US | claimed |
| WO-2004063129-A2 | METHODS FOR NUCLEOPHILIC FLUOROMETHYLATION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2004-07-29 | — | — | WO | claimed |
| US-9329185-B2 | Sulfonate compounds | UNIVERSITY OF MASSACHUSETTS (US) | 2016-05-03 | — | — | US | disclosed |
| US-9329185-B2 | Sulfonate compounds | UNIVERSITY OF MASSACHUSETTS (US) | 2016-05-03 | — | — | US | disclosed |
| US-20140275526-A1 | SULFONATE COMPOUNDS | UNIVERSITY OF MASSACHUSETTS (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275526-A1 | SULFONATE COMPOUNDS | UNIVERSITY OF MASSACHUSETTS (US) | 2014-09-18 | — | — | US | disclosed |
| US-20090291988-A1 | Reversible Inhibitors of Monoamine Oxidase A and B | MERCK FROSST CANADA LTD. (CA) | 2009-11-26 | — | — | US | disclosed |
| EP-1893562-A1 | REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B | Merck Frosst Canada Ltd. (CA) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006133559-A1 | REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B | MERCK FROSST CANADA LTD. (CA) | 2006-12-21 | — | — | WO | disclosed |
| US-7087789-B2 | Methods for nucleophilic fluoromethylation | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2006-08-08 | — | — | US | disclosed |
| US-20040230079-A1 | Methods for nucleophilic fluoromethylation | SOUTHERN CALIFORNIA, UNIVERSITY OF | 2004-11-18 | — | — | US | disclosed |
| WO-2004063129-A2 | METHODS FOR NUCLEOPHILIC FLUOROMETHYLATION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040230079-A1 | Methods for nucleophilic fluoromethylation | PHF2, HAO2, GSTM2 | KIF11 4359/4885NR1I2 3006/4885ACP3 2241/4885 |
| US-20090291988-A1 | Reversible Inhibitors of Monoamine Oxidase A and B | MAOB, MAOA, XDH | KIF11 4535/4885NR1I2 1930/4885ACP3 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.